TUCSON, Ariz., Jan. 4, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that in 2011, the company nearly doubled sales for the second straight year, representing a four-fold increase since 2009.
"This is the first full year that SynCardia has been profitable during the company's 10-year history," said Michael Garippa, SynCardia CEO/President. "Acceptance of the SynCardia temporary Total Artificial Heart as the new standard of care for end-stage biventricular failure is accelerating and as a result, demand is growing rapidly."
There are currently 50 SynCardia Certified Centers worldwide. An additional 39 hospitals are currently in the process of completing SynCardia's Certification Program. In 2011, 29 new centers signed up to undergo certification. In addition, several world-renowned transplant programs performed their first implants of the Total Artificial Heart, including NewYork Presbyterian/Columbia, Texas Heart Institute, Keck Hospital of the University of Southern California, Florence Nightingale Hospital in Istanbul, Turkey and Papworth Hospital in the United Kingdom.
In 2012, SynCardia expects to complete the FDA-approved Investigational Device Exemption (IDE) clinical study of the Freedom® portable driver. Weighing 13.5 pounds, the Freedom driver is the world's first wearable power supply for SynCardia's Total Artificial Heart.&